Andrew Hopkins, Exscientia
BlackRock pushes Exscientia Series C to $100M as AI biotech boom continues
The jury’s still out on whether the first wave of AI companies can significantly change drug development, but investors are increasingly buying into the hype …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
